WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1996003436) EQUINE $g(g)-INTERFERON
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1996/003436    International Application No.:    PCT/GB1995/001732
Publication Date: 08.02.1996 International Filing Date: 21.07.1995
IPC:
A61K 38/00 (2006.01), C07K 14/57 (2006.01)
Applicants: Q-ONE BIOTECH LIMITED [GB/GB]; Todd Campus, West of Scotland Science Park, Glasgow G20 0XA (GB) (For All Designated States Except US).
ONIONS, David, Edward [GB/GB]; (GB) (For US Only).
NICHOLSON, Lesley [GB/GB]; (GB) (For US Only)
Inventors: ONIONS, David, Edward; (GB).
NICHOLSON, Lesley; (GB)
Agent: McCALLUM, William, Potter; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB)
Priority Data:
9414753.5 21.07.1994 GB
Title (EN) EQUINE $g(g)-INTERFERON
(FR) GAMMA-INTERFERON D'ORIGINE EQUINE
Abstract: front page image
(EN)The present invention provides a polynucleotide fragment encoding equine $g(g)-interferon, a recombinant vector comprising such a polynucleotide fragment, a host cell containing said polynucleotide fragment or recombinant vector, a recombinant equine $g(g)-interferon polypeptide, and pharmaceutical compositions comprising recombinant $g(g)-interferon for use as a prophylactic and/or therapeutic agent and also as an adjuvant.
(FR)Cette invention concerne un fragment polynucléotidique codant un gamma-interféron d'origine équine, un vecteur de recombinaison comprenant un fragment polynucléotidique de ce type, une cellule hôte contenant ledit fragment polynucléotidique ou ledit vecteur de recombinaison, un polypeptide de gamma-interféron d'origine équine obtenu par recombinaison, et des compositions pharmaceutiques comprenant le gamma-interféron de recombinaison utilisé comme agent prophylactique et/on thérapeutique et également comme adjuvant.
Designated States: AU, JP, US.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)